# Topical Eflornithine for Pseudofolliculitis Barbae: Randomized Controlled Trial

> **NCT04403282** · PHASE4 · TERMINATED · sponsor: **Walter Reed National Military Medical Center** · enrollment: 9 (actual)

## Conditions studied

- Pseudofolliculitis Barbae

## Interventions

- **DRUG:** Eflornithine Topical
- **DRUG:** Placebo Eflornithine Topical

## Key facts

- **NCT ID:** NCT04403282
- **Lead sponsor:** Walter Reed National Military Medical Center
- **Sponsor class:** FED
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-09-27
- **Primary completion:** 2023-06-22
- **Final completion:** 2023-06-22
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Vaniqa no longer manufactured
- **Last updated:** 2024-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04403282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04403282, "Topical Eflornithine for Pseudofolliculitis Barbae: Randomized Controlled Trial". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT04403282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*